Oura’s $2.1 Billion IPO Pairs Strong Demand Signals With Heavy Insider Selling

SAN FRANCISCO, September 22, 2026. Oura is asking public investors to value a profitable, fast-growing consumer health platform at as much as $15.6 billion, with Eli Lilly and Dragoneer signaling up to $400 million of demand. The catch is in the allocation of the capital: most of the base deal belongs to existing holders, and nearly all the cash reaching Oura is slated for employee equity-related taxes.

The smart-ring maker is marketing 50 million shares at $40 to $44 each, a $2.0 billion to $2.2 billion offering. Oura itself is selling 13.5 million shares, while existing stockholders are offering 36.5 million, according to the company’s September 21 amended prospectus. At the $42 midpoint, the deal would raise $2.1 billion, with 73% of the base shares coming from sellers. A 7.5 million-share overallotment option is also entirely secondary, which could lift stockholder sales to 44 million shares.

That split is the central issue for IPO investors. Oura estimates net proceeds of $532.6 million from its primary shares at the midpoint, then plans to use approximately $526.4 million to cover tax withholding and remittance tied to the net settlement of restricted stock units. Only the remainder is designated for general corporate purposes such as technology development, working capital, operating expenses and capital expenditures. IPOGrid reads this as a liquidity and capitalization event more than a conventional growth-capital raise. The company enters the offering with a stronger operating profile, but the IPO itself adds only about $6.2 million of cash after the expected RSU tax payment on those assumptions.

The demand has recognizable names

The book has more definition than most consumer technology offerings at launch. Eli Lilly has indicated interest in buying up to $100 million of stock, while funds affiliated with Dragoneer have indicated interest in as much as $300 million, all at the IPO price and on the same terms as other buyers. Those are nonbinding indications, so they should not be treated as committed orders. Still, the $400 million headline equals about 19% of the deal at the midpoint and gives the roadshow an institutional anchor.

Lilly’s interest also carries strategic context. The prospectus says LillyDirect is among the connected-care partners that link Oura-generated wellness insights with care and treatment-support programs. Lilly separately holds a $50 million SAFE that is expected to convert into 1.19 million common shares immediately before the offering at an assumed $42 price. Our interpretation is that Lilly’s participation lends credibility to Oura’s healthcare ambitions, although it does not remove the execution risk in moving beyond a premium consumer wearable.

Goldman Sachs is the representative of an 18-firm syndicate that includes Morgan Stanley, J.P. Morgan, Allen & Company and Jefferies near the top of the cover. Reuters identified Goldman, Morgan Stanley and J.P. Morgan as the lead underwriters. The breadth of that bank group should support distribution, while a directed share program reserves up to 7.5% of the offering for people and entities selected by management.

Growth and profitability support the valuation discussion

Oura’s numbers explain why the issuer can attempt a large exit-heavy deal. Revenue reached $1.21 billion for the nine months ended June 30, up 74% from $697.6 million a year earlier. Gross margin expanded to 55% from 51%, net income rose to $60.8 million from $1.6 million, and adjusted EBITDA reached $106.7 million. Operating cash flow was $328.0 million, compared with $135.3 million in the prior-year period.

The recurring layer is growing, but hardware still drives the model. Oura generated $974.0 million of hardware revenue and $240.5 million of membership revenue during the nine-month period, an 80% to 20% mix. It had 5.0 million paid members at June 30 and reported approximately 85% weighted-average 12-month paid-member retention. That subscription base makes the business more durable than a one-time device sale, while the reviewer’s concern is that investors are still underwriting a hardware-led consumer cycle at a premium valuation.

The proposed range implies a market capitalization of about $12.8 billion to $14.1 billion using the prospectus’s roughly 320.9 million pro forma shares outstanding, while Reuters calculates a $15.62 billion fully diluted valuation at the top. At $44, that is roughly 9.6 times annualized revenue based on the latest nine-month period. The multiple asks investors to believe the combination of ring sales, subscription growth and healthcare partnerships can sustain unusually high growth.

Oura also remains exposed to competition from Samsung and other wearables companies, product concentration, tariffs and the economics of replacing or upgrading hardware. Its own filing says only about 2% of global wearable shipments in the year ended June 30 were Oura Rings, leaving substantial room to grow but also placing the company inside a much broader device market.

The roadshow therefore has two opposing signals. Named demand, profitability and a top-tier syndicate give the IPO real support. Heavy secondary selling and an RSU-tax use of proceeds limit the fresh balance-sheet benefit. Oura deserves attention because the operating company looks ready for public scrutiny. Whether the stock is ready depends on how much valuation investors will grant a fast-growing subscription story that still earns four dollars out of five from hardware.